Our objective was to perform an early target validation of the effects of a Nrf2 pathway activator, dimethyl fumarate, on the incidence of chronic diseases (T2D, CVD and CKD) in human populations prior to embarking on lengthy preclinical drug development initiatives in related indications. This evidence concerns the gene NFE2L2 and chronic kidney disease.